Talotta, R.; Berzi, A.; Doria, A.; Batticciotto, A.; Ditto, M.C.; Atzeni, F.; Sarzi-Puttini, P.; Trabattoni, D.
The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. Int. J. Mol. Sci. 2017, 18, 2127.
https://doi.org/10.3390/ijms18102127
AMA Style
Talotta R, Berzi A, Doria A, Batticciotto A, Ditto MC, Atzeni F, Sarzi-Puttini P, Trabattoni D.
The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. International Journal of Molecular Sciences. 2017; 18(10):2127.
https://doi.org/10.3390/ijms18102127
Chicago/Turabian Style
Talotta, Rossella, Angela Berzi, Andrea Doria, Alberto Batticciotto, Maria Chiara Ditto, Fabiola Atzeni, Piercarlo Sarzi-Puttini, and Daria Trabattoni.
2017. "The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses" International Journal of Molecular Sciences 18, no. 10: 2127.
https://doi.org/10.3390/ijms18102127
APA Style
Talotta, R., Berzi, A., Doria, A., Batticciotto, A., Ditto, M. C., Atzeni, F., Sarzi-Puttini, P., & Trabattoni, D.
(2017). The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. International Journal of Molecular Sciences, 18(10), 2127.
https://doi.org/10.3390/ijms18102127